Inhibikase Therapeutics, Inc. announced the appointment of Mark Iwicki as its new Chief Executive Officer, effective February 14, 2025. Mr. Iwicki replaces Dr. Milton H. Werner, the company's founder.
Concurrently, Amit Munshi, a biopharmaceutical industry veteran and current board member, was appointed as the independent Chair of the Board, also effective February 14, 2025. Mr. Munshi succeeds Roberto Bellini, who will continue to serve as a director.
Mr. Iwicki brings over 30 years of biopharmaceutical industry experience, with a strong background in cardiovascular diseases and Pulmonary Arterial Hypertension (PAH). His appointment is expected to drive the company's strategic focus on advancing IkT-001Pro through clinical development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.